$MTEM
Molecular Templates, Inc. Stock $mtem

$mtem Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000119312513424128 Filed on November 04, 2013

Income Statement

Concept	2013 Q4	2013 Q3	2012 Q3
Revenue	$3.210M	$3.180M	$1.800M
YoY Change	58.91%	76.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.450M	$2.050M	$1.740M
YoY Change	32.43%	17.82%	32.82%
% of Gross Profit
Research & Development	$8.530M	$6.350M	$4.039M
YoY Change	38.47%	57.22%	-37.68%
% of Gross Profit
Depreciation & Amortization	$420.0K	$430.0K	$340.0K
YoY Change	23.53%	26.47%	112.5%
% of Gross Profit
Operating Expenses	$10.99M	$8.401M	$5.780M
YoY Change	37.2%	45.35%	-25.79%
Operating Profit		-$5.220M	-$3.983M
YoY Change		31.06%	-48.86%
Interest Expense	$30.00K	$34.00K	$25.00K
YoY Change	0.0%	36.0%	150.0%
% of Operating Profit
Other Income/Expense, Net	$230.0K	$6.380M	$2.970M
YoY Change	-99.33%	114.81%	-18.85%
Pretax Income	-$7.510M	$1.193M	-$991.0K
YoY Change	-126.45%	-220.38%	-76.0%
Income Tax	$80.00K	$17.00K	$0.00
% Of Pretax Income		1.42%
Net Earnings	-$7.589M	$1.176M	-$991.0K
YoY Change	-126.73%	-218.67%	-75.98%
Net Earnings / Revenue	-236.42%	36.98%	-55.06%
Basic Earnings Per Share	-$0.13	$0.02	-$0.02
Diluted Earnings Per Share	-$0.13	-$0.08	-$0.06
COMMON SHARES
Basic Shares Outstanding	59.22M shares	58.54M	55.65M shares
Diluted Shares Outstanding		63.56M	64.41M shares

Balance Sheet

Concept	2013 Q4	2013 Q3	2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$65.70M	$91.90M	$65.80M
YoY Change	-7.2%	39.67%	160.08%
Cash & Equivalents	$7.279M	$4.001M	$8.634M
Short-Term Investments	$58.40M	$87.90M	$57.20M
Other Short-Term Assets	$2.200M	$1.800M	$1.100M
YoY Change	83.33%	63.64%	37.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$86.01M	$99.28M	$84.43M
YoY Change	-1.87%	17.58%	223.49%
LONG-TERM ASSETS
Property, Plant & Equipment	$686.0K	$708.0K	$728.0K
YoY Change	-15.52%	-2.75%	82.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$16.40M
YoY Change
Other Assets	$1.059M	$1.059M	$1.059M
YoY Change	0.0%	0.0%	253.0%
Total Long-Term Assets	$18.11M	$1.767M	$1.787M
YoY Change	867.88%	-1.12%	123.38%
TOTAL ASSETS
Total Short-Term Assets	$86.01M	$99.28M	$84.43M
Total Long-Term Assets	$18.11M	$1.767M	$1.787M
Total Assets	$104.1M	$101.0M	$86.22M
YoY Change	16.31%	17.2%	220.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.689M	$1.375M	$739.0K
YoY Change	86.01%	86.06%	146.33%
Accrued Expenses	$3.161M	$2.489M	$1.817M
YoY Change	40.05%	36.98%	-64.37%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$27.02M	$24.88M	$16.19M
YoY Change	54.81%	53.67%	199.8%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$100.6M	$93.70M	$114.1M
YoY Change	17.11%	-17.88%	850.83%
Total Long-Term Liabilities	$100.6M	$93.70M	$114.1M
YoY Change	17.11%	-17.88%	850.83%
TOTAL LIABILITIES
Total Short-Term Liabilities	$27.02M	$24.88M	$16.19M
Total Long-Term Liabilities	$100.6M	$93.70M	$114.1M
Total Liabilities	$127.6M	$118.5M	$130.3M
YoY Change	23.43%	-9.02%	648.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$351.7M	-$344.1M	-$351.7M
YoY Change	8.79%	-2.15%
Common Stock	$328.2M	$326.6M	$307.6M
YoY Change	6.07%	6.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$23.48M	-$17.50M	-$44.08M
YoY Change
Total Liabilities & Shareholders Equity	$104.1M	$101.0M	$86.22M
YoY Change	16.31%	17.2%	220.51%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2012 Q3
OPERATING ACTIVITIES
Net Income	-$7.589M	$1.176M	-$991.0K
YoY Change	-126.73%	-218.67%	-75.98%
Depreciation, Depletion And Amortization	$420.0K	$430.0K	$340.0K
YoY Change	23.53%	26.47%	112.5%
Cash From Operating Activities	-$9.610M	-$7.420M	-$2.250M
YoY Change	-292.97%	229.78%	-64.51%
INVESTING ACTIVITIES
Capital Expenditures	-$50.00K	-$10.00K	-$100.0K
YoY Change	-66.67%	-90.0%	-68.75%
Acquisitions
YoY Change
Other Investing Activities	$12.81M	$5.600M	$790.0K
YoY Change	-541.72%	608.86%	-50.0%
Cash From Investing Activities	$12.77M	$5.580M	$680.0K
YoY Change	-517.32%	720.59%	-46.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	120.0K	1.420M	1.900M
YoY Change	-73.91%	-25.26%	245.45%
NET CHANGE
Cash From Operating Activities	-9.610M	-7.420M	-2.250M
Cash From Investing Activities	12.77M	5.580M	680.0K
Cash From Financing Activities	120.0K	1.420M	1.900M
Net Change In Cash	3.280M	-420.0K	330.0K
YoY Change	37.82%	-227.27%	-107.28%
FREE CASH FLOW
Cash From Operating Activities	-$9.610M	-$7.420M	-$2.250M
Capital Expenditures	-$50.00K	-$10.00K	-$100.0K
Free Cash Flow	-$9.560M	-$7.410M	-$2.150M
YoY Change	-286.35%	244.65%	-64.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8634000
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	59174123	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3361581	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	59174123	shares
CY2013Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.66
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6560016	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.64
CY2013Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	8300000	shares
CY2013Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	6504707	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.67
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2013Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2013Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2489000
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	651000
CY2013Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8291000
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2426000
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1375000
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	702000
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	24877000
CY2013Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	38000
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	-17500000
CY2013Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	326492000
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	238000
CY2013Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	23790000
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-344089000
CY2013Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	12722000
CY2013Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	250000
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	59000
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	101045000
CY2013Q3	us-gaap	Liabilities Liabilities	118545000
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	674000
CY2013Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	69628000
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	161000
CY2013Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	87913000
CY2013Q3	us-gaap	Assets Current AssetsCurrent	99278000
CY2013Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	87876000
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1059000
CY2013Q3	us-gaap	Assets Assets	101045000
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	10518742
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4001000
CY2013Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	20437000
CY2013Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	8034963
CY2013Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	87913000
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1819000
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10534778
CY2013Q3	us-gaap	Other Receivables OtherReceivables	5545000
CY2013Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	11600000
CY2013Q3	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	91914000
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	708000
CY2013Q3	thld	Plan Participants Withheld To Purchase Stock PlanParticipantsWithheldToPurchaseStock	100000
CY2013Q3	thld	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses Accumulated In Investments AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLossesAccumulatedInInvestments	6000
CY2013Q3	thld	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	6000
CY2013Q3	thld	Available For Sale Debt Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestments	43000
CY2013Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	59224123	shares
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5882000
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56431207	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56431207	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.18
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5098972	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2257000
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5750000
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	908000
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17451000
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	11000
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-13853000
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	309343000
CY2012Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	32558000
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-323263000
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	8536000
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	268000
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	56000
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	89521000
CY2012Q4	us-gaap	Liabilities Liabilities	103374000
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	53097000
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	59819000
CY2012Q4	us-gaap	Assets Current AssetsCurrent	87650000
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	59808000
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1059000
CY2012Q4	us-gaap	Assets Assets	89521000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11029000
CY2012Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	59819000
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1167000
CY2012Q4	us-gaap	Other Receivables OtherReceivables	15635000
CY2012Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	70825000
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	812000
CY2012Q4	thld	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	7000
CY2012Q4	thld	Available For Sale Debt Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestments	18000
	dei	Trading Symbol TradingSymbol	THLD
	dei	Entity Registrant Name EntityRegistrantName	THRESHOLD PHARMACEUTICALS INC
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	dei	Entity Central Index Key EntityCentralIndexKey	0001183765
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59871000	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2509000	shares
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	19760000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.15
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M29D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.10
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.59
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1653500	shares
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57362000	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y4D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y9M26D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	127153	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	65303	shares
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	652000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20799000
	us-gaap	Contracts Revenue ContractsRevenue	9283000
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	18000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	88951000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20826000
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	104000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-21383000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18250000
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-2559000
	us-gaap	Increase Decrease In Derivative Assets And Liabilities IncreaseDecreaseInDerivativeAssetsAndLiabilities	-2559000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-20705000
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-557000
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-10090000
	us-gaap	Net Income Loss NetIncomeLoss	-20826000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	106000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	27000
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2541000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	100000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6732000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2269000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	20717000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1800000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	500000
	us-gaap	Share Based Compensation ShareBasedCompensation	3556000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1094000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-7028000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	56797000
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	3203000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	232000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	467000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2269000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29057000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20801000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	200000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3556000
	us-gaap	Deferred Revenue Revenue Recognized DeferredRevenueRevenueRecognized	9300000
	us-gaap	Operating Expenses OperatingExpenses	27533000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	121000
	thld	Exercise Of Warrants Liability Measured At Fair Value ExerciseOfWarrantsLiabilityMeasuredAtFairValue	11327000
	thld	Reclassifications Of Fair Value From Liability To Permanent Equity ReclassificationsOfFairValueFromLiabilityToPermanentEquity	11300000
	thld	Reimbursement Expenses ReimbursementExpenses	11600000
	thld	Weighted Average Maturity For Available For Sale Securities WeightedAverageMaturityForAvailableForSaleSecurities	P7M
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.86
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53516000	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.86
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	24925000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53516000	shares
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	606000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-99508000
	us-gaap	Contracts Revenue ContractsRevenue	3846000
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-120000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	75413000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-99523000
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	55000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-99523000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14006000
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-85572000
	us-gaap	Increase Decrease In Derivative Assets And Liabilities IncreaseDecreaseInDerivativeAssetsAndLiabilities	-85572000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-99523000
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	17457000
	us-gaap	Net Income Loss NetIncomeLoss	-99523000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	328000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	15000
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1980000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	200000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5229000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21446000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	53654000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1400000
	us-gaap	Share Based Compensation ShareBasedCompensation	2087000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	668000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2752000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	21522000
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	10600000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	80000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1650000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	21446000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-43619000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12623000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	400000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2087000
	us-gaap	Deferred Revenue Revenue Recognized DeferredRevenueRevenueRecognized	3800000
	us-gaap	Operating Expenses OperatingExpenses	17852000
	thld	Reimbursement Expenses ReimbursementExpenses	10000000
CY2012Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2012Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64405000	shares
CY2012Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	8751000	shares
CY2012Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2012Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55654000	shares
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-964000
CY2012Q3	us-gaap	Contracts Revenue ContractsRevenue	1797000
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-991000
CY2012Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	25000
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3958000
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3983000
CY2012Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	2967000
CY2012Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-991000
CY2012Q3	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-2967000
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-991000
CY2012Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	27000
CY2012Q3	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	100000
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1741000
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4039000
CY2012Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	944000
CY2012Q3	us-gaap	Deferred Revenue Revenue Recognized DeferredRevenueRevenueRecognized	1800000
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	5780000
CY2012Q3	thld	Reimbursement Expenses ReimbursementExpenses	5000000
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2013Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63561000	shares
CY2013Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	5019000	shares
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2013Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58542000	shares
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1241000
CY2013Q3	us-gaap	Contracts Revenue ContractsRevenue	3181000
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1176000
CY2013Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	34000
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5203000
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5220000
CY2013Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	6379000
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1193000
CY2013Q3	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-6379000
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	1176000
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	65000
CY2013Q3	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	36000
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2051000
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6350000
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1231000
CY2013Q3	us-gaap	Deferred Revenue Revenue Recognized DeferredRevenueRevenueRecognized	3200000
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	8401000
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17000
CY2013Q3	thld	Reclassifications Of Fair Value From Liability To Permanent Equity ReclassificationsOfFairValueFromLiabilityToPermanentEquity	3800000
CY2013Q3	thld	Reimbursement Expenses ReimbursementExpenses	5500000

Files In Submission

Name	View Source	Status
0001193125-13-424128-index-headers.html	Edgar Link	pending
0001193125-13-424128-index.html	Edgar Link	pending
0001193125-13-424128.txt	Edgar Link	pending
0001193125-13-424128-xbrl.zip	Edgar Link	pending
d600331d10q.htm	Edgar Link	pending
d600331dex311.htm	Edgar Link	pending
d600331dex312.htm	Edgar Link	pending
d600331dex321.htm	Edgar Link	pending
d600331dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
thld-20130930.xml	Edgar Link	completed
thld-20130930.xsd	Edgar Link	pending
thld-20130930_cal.xml	Edgar Link	unprocessable
thld-20130930_def.xml	Edgar Link	unprocessable
thld-20130930_lab.xml	Edgar Link	unprocessable
thld-20130930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MTEM
Molecular Templates, Inc. Stock $mtem

2013 Q4 Form 10-Q Financial Statement

#000119312513424128 Filed on November 04, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MTEM Molecular Templates, Inc. Stock $mtem

2013 Q4 Form 10-Q Financial Statement

#000119312513424128 Filed on November 04, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MTEM
Molecular Templates, Inc. Stock $mtem